MedTrace Logo

Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

NCT04648189 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-10-19

No results posted yet for this study

Summary

Cetuximab to reduce the amound of circulating tumor cells in early stage NSCLC

Conditions

Interventions

DRUG

Cetuximab

A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery

Sponsors & Collaborators

  • Dutch Cancer Society

    collaborator OTHER

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Egbert Smit, prof · The Netherlands Cancer Institute-Antoni van Leeuwenhoek

  • Marjolein van Egmond, prof · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2022-09-19
Completion
2022-09-19

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04648189 on ClinicalTrials.gov